Does the somatostatin analogue octreotide have a role in pain relief?

Pain Clinic

Volumn 8, Issue 4, 1996, Pages 369-375

  Chrubasik, S ^a   Ziegler, R ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Analgesia; Octreotide; Somatostatin

Indexed keywords

NEUROTRANSMITTER; OCTREOTIDE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE;

ANALGESIA; CANCER PAIN; DOSE RESPONSE; DRUG HALF LIFE; HEADACHE; HUMAN; HYPOPHYSIS TUMOR; INTRATHECAL DRUG ADMINISTRATION; NOCICEPTION; PAIN; REVIEW; SIDE EFFECT; SPINAL CORD; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029551697     PISSN: 01691112     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Massari VJ, Tizabi J, Park CH, Moody TW, Heike CJ, O'Donohue, TL. Distribution and origin of bombesin, substance P and somatostatin in cat spinal cord. Peptides 1983; 4: 673-81.
2. Kuraishi Y, Hirota N, Sato Y, Hino Y, Satoh M, Takagi, H. Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. Brain Res 1985; 325: 294-98.
3. Morton CR, Hutchison WD, Hendry IA, Duggan AW. Somatostatin: evidence for a role in thermal nociception. Brain Res 1988; 488: 89-96.
4. Chrubasik J, Meynadier J, Blond S et al. Somatostatin, a potent analgesic. Lancet 1984; ii: 1208-9.
5. Carli P, Ecoffey C, Chrubasik J, Benlabed M, Gross JB, Samii K. Spread of analgesia and ventilatory response to carbon-dioxide following epidural somatostatin. Eur J Anaesthesiol 1989; 6: 257-63.
6. Hügler P, Mendl G, Landgraf R, Madler C, Martin E. First expierence using epidural somatostatin (S) in extra-corporeal-shock-wave-lithotripsy (ESWL). Anaesthetist 1987; 36: 388.
7. Gulya K, Pelton JT, Hruby VJ, Yamamura HI. Cyclic somatostatin octapeptide analogues with high affinity and selectivity toward mu opioid receptors. Life Sci 1986; 38: 2221-9.
8. Harfstrand A, Kalia M, Fuxe K, Kaijser L, Agnati LF. Somatostatin-induced apnea: interaction with hypoxia and hypercapnea in the rat. Neuroscience Lett 1984; 50: 25-9.
9. Gaumann DM, Yaksh TL, Post C, Wilcox GL, Rodriguez M. Intrathecal somatostatin in cat and mouse studies on pain, motor behavior, and histopathology. Anesth Analg 1989; 68: 623-32.
10. Chrubasik J, Meynadier J, Scherpereel P, Wünsch E. The effect of epidural somatostatin on postoperative pain. Anesth Analg 1985; 64: 1085-8.
11. Filuk RB, Berezanski DJ, Anthonisen NR. Depression of hypoxic ventilatory response in humans by somatostatin. J Appl Physiol 1988; 65: 1050-4.
12. Chrubasik J. Intrathecal somatostatin. Ann NY Acad Sci 1988; 531: 133-46.
13. Chrubasik J, Meynadier J, Scherpereel P, Magora F, Davidson JT, Wünsch E. Erste Untersuchungen zur intraoperativen Anwendung spinal applizierten Somatostatins. Anästh Intensivther Notfallmed 1985; 20: 139-42.
14. Desborough JP, Edlin SA, Burrin JM, Bloom SR, Morgan M, Hall GM. Hormonal and metabolic responses to cholecystectomy: comparison of extradural somatostatin and diamorphine. Br J Anaesth 1989; 63: 508-15.
15. Meynadier J, Chrubasik J, Dubar M, Wünsch E. Intrathecal somatostatin in two terminally ill patients. Pain 1985; 23: 9-12.
16. 16a. Mollenholt P, Rawal N, Gordh T, Olsson Y. Intrathecal and epidural somatostatin for patients with cancer. Anesthesiology 1994; 81: 534-42.
17. 16b. Mollenholt P, Post C, Paulsson I, Rawal N. Intrathecal and epidural somatostatin in rats: can antinociception, motor effects and neurotoxicity be separated? Pain 1990; 43: 363-70
18. Volk B, Rosenmann E. Somatostatin neurotoxicity in animals. Anesth Analg 1990; 70: 669-70.
19. Gaumann DM, Yaksh TL. Intrathecal somatostatin in rats: antinociception only in the presence of toxic effects. Anesthesiology 1988; 68: 733-42.
20. Freedman J, Post C, Kahrsröm J, Mollenholt P, Owman C, Alari L, Hökfelt T. Vasoconstrictor effects in spinal cord of the substance P antagonist (D-ARG, D-TRP, LEU) - substance P (Spantide) and somatostatin and interaction with thyrotropin releasing hormone. Neuroscience 1988; 27: 267-78.
21. Kutz K, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986; 21 (Suppl 119): 65-72.
22. Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 1979; 48: 50-2.
23. Pozo del E, Neufeld M, Schluter K. Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 1986; 111: 433-9.
24. Lightman SL, Fox P, Dunne MJ. The effect of SMS 210-995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male, volunteers. Scand J Gastroenterol 1986; 21 (Suppl): 84-95.
25. Gyr KE, Whitehouse I, Beglinger C. Human pharmacological effects of SMS 201 -995 on gastric secretion. Scand J Gastroenterol 1986; 21 (Suppl 119): 96-102.
26. Lembke B, Creutzfeldt W, Schleser S et al. Effect of the somatostatin analogue Sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987; 36: 108-24.
27. Schusdziarra V, Schmid R. Physiological and pathophysiological aspects of somatostatin. Scand J Gastroenterol 1986; 21 (Suppl 119): 29-41.
28. Samnegard H, Thulin L, Tyden G, Hallberg D, Efendic S. Circulatory effects of somatostatin in anaesthetized dogs. Acta Chir Scand 1979; 145: 209-12.
29. Price BA, Jaffe BM, Zinner MJ. The effect of somatostatin on central hemodynamics, renal blood flow, and renal function in dogs. Surgery 1985; 3: 285-9.
30. Becker RHA, Scholtholt J, Schölkens BA, Jung W, Speth O. A microscopic study on the effects of somatostatin and secretin on regional blood flow in anesthetized dogs. Regul Peptides 1982; 4: 341-51.
31. Sieber C, Gnadinger M, del Pozo E et al. Effect of a new somatostatin analogue SMS 201-995 (Sandostatin) on the renin-aldosterone axis. Clin Endocrinol 1988; 28: 25-32.
32. Chapman V, Dickenson AH. The effects of Sandostatin and somatostatin on nociceptive transmission in the dorsal horn of the rat spinal cord. Neuropeptides 1992; 23: 147-52.
33. Foot RW, Niemrich G. Weaking of naloxone antagonism in vitro and in vivo with octreotide (SMS 201-995). Eur J Pharmacol 1987; 141: 325-30.
34. Fanselow MS, Calcagnetti DJ, Helmstetter FJ. Role of mu and kappa opioid receptors in conditional fear-induced analgesia: The antagonistic actions of norbinaltorphimine and the cyclic somatostatin octapeptide, cys2 tyr3 orn7-amide. J Pharm Exper Ther 1988; 250: 825-30.
35. Hirning L, Peterson L, Pelton J, Hruby V, Burkes T. Opioid antagonist action of conformationally constrained somatostatin analogues in vitro. Fed Proc 1985; 44: 611 (Abstr. 1171).
36. Musolino NR, Marino R, Bronstein MD. Headache in acromegaly: dramatic improvement with the somatostatin analogue SMS 201-995. Clin J Pain 1990; 6: 243-5.
37. Webb SM, Cabezas R, Montanes de Leiva R. Efecto analgesico de un analoge de la somatostatina, SMS 201-995, sobre la cefalea asociada a tumor hipofisario. Med Clin Barcelona 1989; 93: 501-2.
38. Schmidt K, Althoff PH, Harris AG, Prestele H, Schumm-Draeger PM, Usadel KH. Analgesic effect of the somatostatin analogue octreotide in two acromegalic patients: a double-blind study with long-term follow-up. Pain 1993; 53: 223-7.
39. Williams ST, Eoltering EA, O'Dorisio TM, Fletcher WS. Effects of Sandostatin on pancreatic exocrine function. Biomed Res 1989; (Suppl 1): 155.
40. Popovic V, Paunovic VR, Micic D, Nesovic M, Kendereski A, Djordjevic P, Manojlovic D, Micic J. The analgesic effect and developement of dependency to somatostatin analogue (octreoide) in headache associated with acromegaly. Hormone Metabol Res 1988; 20: 250-1.
41. Penn RD, Paice JA, Kroin JS. Octreotide: a potent new non-opiate analgesic for intrathecal infusion. Pain 1992; 49: 13-9.
42. Candrina R, Galli G. Intraventricular octreotide for cancer pain. J Neurosurg 1992; 76: 336-7.
43. Tucci A, Carteni G, Biglietto M, Nicolella GP, Riccardi F, Pacilio G. A phase n study of octreotide in metastatic advanced prostotatic cancer (MAPC). Eur J Cancer 1991; 27(Suppl 3): S88.
44. Altavilla G, Adamo V, Alafaci E, Buemi B, Caristi N, D'Aquino A, De Francesco F, Toscano G. Somatostatin analog octreotide in the treatment of advanced colon and pancreatic adenocarcinomas. Eur J Cancer 1991; 27 (Suppl 2): 74.
45. Schmalz MJ, Soergel KH, Johanson JF. The effect of octreotide (Sandostatin®), on the pain of chronic pancreatitis. Gastroenterology 1992; 102 (Suppl 2): A290.
46. Ellis WV. Octreotide, a small peptide, alleviates burning pain and hyperaesthesia: a preliminary study. Pain Clinic 1990; 3: 239-42.
47. Barnard L, Grantham W, Lamberton P, O'Dorisio TM, Jackson IM. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Ann Intern Med 1986; 105: 865-71.
48. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Intern Med 1991; 151: 1473-578.
49. Mehltretter G, Heinz S, Schoppohl J, von Werder K, Müller OA. Long-term treatment with SMS 201-995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion. Klin Wochenschr 1991; 69: 83-90.
50. Arnold R, Neuhaus C, Benning R, Schwerk WB, Trautmann ME, Joseph K, Bruns C. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg 1993; 17: 511-9.
51. Parris WCV, Oates JA, Kambam J, Shmerling R, Sawyers JF. Pretreatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome. Can J Anaesth 1988; 35: 413-6.
52. Amjad H, Ullah MA. Octreotide acetate for refractory diarrhea in radiation induced enteritis. Clin Res 1993; 41: 360A.
53. Carteni G, Tucci A, Biglietto M, Nicolella GP, Riccardi F, Campagna A, Pacilio G. Octreotide in therapy of diarrhea chemotherapy related. Eur J Cancer 1991; 27: S288.
54. Cascinu S, Fedeli A, Luzi Fedeli S, Catalane G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993; 11: 138-51.
55. René E, Bonfils S. Control of severe diarrhea with somatostatin. N Engl J Med 1984; 311: 598-9.
56. Walker JJ, Kaplan DS. Efficacy of the somatostatin analog octreotide in the treatment of two patients with refractory diabetic diarrhea. Am J Gastroenterol 1993; 88: 765-7.
57. Ahren B, Tranberg K-G, Bengmark S. Treatment of pancreatic fistula with the somatostatin analogue SMS 201-995. Br J Surg 1988; 75: 718.
58. Walker JJ, Kaplan DS. Efficacy of the somatostatin analog octreotide in the treatment of two patients with refractory diabetic diarrhea. Am J Gastroenterol 1993; 88: 765-7.
59. Sung JJY, Chung SCS, Lai CW, Chan FKL, Leung JWC, Yung MY. Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. Lancet 1993; 342: 637-41.
60. McKnee RF, Garden OJ, Anderson JR, Carter DC. A comparison of SMS 201-995 and oesophageal tamponade in the control of acute variceal haemorrhage. HPB Surg 1992; 6: 7-17.
61. Silvain C, Carpentier S, Sauereau D et al. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology 1993; 18: 61-5.
62. Hallemans R, Naeije R, Melot C, Mols P, Reding R. Systemic and pulmonary haemodynamic effects of somatostatin. Lancet 1981; i: 1270.
63. Gyr K, Kayasseh L. Somatostatin bei akuten oberen gastrointestinalen Blutungen. Münch Med Wochenschr 1987; 129: 736-8.
64. Büchler M, Friess H, Klempa I et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg 1992; 163: 125-30.
65. Catnach SM, Anderson JV, Fairclough PD et al. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly. Gut 1993; 34: 270-3.
66. Leblanc R, Gauthier S, Gauvin M, Quirion R, Palmour R, Masson H. Neurobehavioral effects of intrathecal somatostatinergic treatment in subhuman primates. Neurology 1987; 38: 1887-90.
67. Kroin JS, O'Dorisio TM, Penn RD, Haklin MF, Howe BA. Distribution of a somatostatin analog after continuous intraventricular administration. Neurosurgery 1989; 24: 744-8.